AI assistant
Humacyte, Inc. — Director's Dealing 2023
Sep 15, 2023
33410_dirs_2023-09-15_87bdb10f-970c-445f-8582-c84e0bec7932.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2023-09-14
Reporting Person: Niklason Laura E (Director, President, CEO and Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-09-14 | Common Stock | S | 2000000 | $2.78 | Disposed | 6191140 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1270240 | Direct |
| Common Stock | 510161 | Indirect |
Footnotes
F1: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.